Meropenem Olikla

Meropenem, the active ingredient in Meropenem Olikla, is a carbapenem antibiotic presented as an injectable powder for intravenous use. It is employed to treat severe bacterial infections in hospitalized patients, including intra‑abdominal, urinary, pulmonary and bloodstream infections.

GNH USA supplies Meropenem Olikla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections affecting various organ systems.

- Complicated intra‑abdominal infections: provides bacterial eradication and clinical cure in patients with perforated or postoperative abdominal infections. - Complicated urinary tract infections: eliminates resistant uropathogens causing pyelonephritis and catheter‑associated UTIs. - Hospital‑acquired pneumonia: achieves microbiological clearance in ventilated or non‑ventilated patients with nosocomial pneumonia. - Septicemia: rapidly reduces bacterial load in bloodstream infections, improving survival outcomes.

Adverse reactions may occur with any intravenous antibiotic and should be monitored during therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal discomfort. - Diarrhea: may be watery and self‑limiting. - Vomiting: occasional episodes during infusion. - Headache: transient and usually resolves after treatment. - Rash: erythematous skin eruption. - Elevated liver enzymes: transient increase in AST/ALT.

Serious or Rare Side Effects: - Anaphylaxis: severe hypersensitivity requiring immediate intervention. - Seizures: especially in patients with renal impairment or CNS disorders. - Clostridioides difficile infection: colitis associated with antibiotic use. - Severe neutropenia: marked reduction in white blood cells. - Acute renal failure: sudden decline in kidney function. - Stevens‑Johnson syndrome: rare mucocutaneous reaction.

Careful assessment and monitoring are essential when using Meropenem.

- Renal function assessment: adjust dosing in patients with impaired clearance. - Hepatic monitoring: observe liver enzymes during prolonged therapy. - Dose adjustment in renal impairment: calculate based on creatinine clearance. - Seizure risk: avoid or use cautiously in individuals with a history of seizures. - Hypersensitivity screening: discontinue if signs of allergic reaction appear. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Meropenem may interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Valproic acid: concomitant use can reduce antiepileptic levels, increasing seizure risk. - Other carbapenems: combined use may increase toxicity without added benefit. - High‑dose aminoglycosides: additive nephrotoxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor renal function and electrolytes. - NSAIDs: watch for reduced renal clearance. - Warfarin: observe INR for potential anticoagulation changes. - Probenecid: may increase plasma concentrations of Meropenem.